Yes, Abbvie paid the $21billion knowing that Jensen would continue getting their 50% profit share.
With that sharing in place, the drug has added some $30billion cummulatively to AbbVie's revenue, so they have some very well.
The revenues are going down due to increasing competition, but they still get over 4billion a year from that drug alone.
Noting too that they acquired the company itself with its asset (not just the drug asset)! Perhaps there is more to come?
CPACS: Research, Results, Market Comparisons, and Valuations, page-237
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.58 |
Change
0.000(0.00%) |
Mkt cap ! $269.2M | |||
| Open | High | Low | Value | Volume |
| $1.60 | $1.60 | $1.56 | $131.8K | 83.28K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1478 | $1.58 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.59 | 200 | 1 |
View Market Depth
| Last trade - 13.50pm 11/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |